Literature DB >> 20002000

Prevalence of resistence to activated protein C (APC-resistance) in blood donors in Kosovo.

Ymer Mekaj1, Bukurije Zhubi, Hakif Hoxha, Remzije Belegu, Agon Mekaj, Ermira Miftari, Mazllum Belegu.   

Abstract

One of the most frequent hereditary causes of thrombophilia is, without a doubt, resistance to Activated Protein C (APC-resistance), which is a consequence of point mutation in gene coding for coagulation Factor V (Factor V Leiden) in 90-95% of cases. The aim of this paper was to determine prevalence of APC-resistance in a group of healthy blood donors. The size of the group is quite representative of Kosovo Albanians. A total of 944 blood donors were examined (537 males and 407 females), for whom APC-resistance was determined by functional methods of coagulation using the kit ACTICLOT(R) Protein C Resistance. Method is based on the test of APTT determined twice: first in the presence and second in the absence of activated Protein C (APC). The ratio of these two values constitutes is called Activated Protein C- Sensitivity Ratio (APC-SR). From 944 examined donors, pathologic values of APC-SR (1,3-1,9) were found in 32 persons (3,4% of the total number). The distribution among sexes was 3,35% (18/537) in male and 3,43% (14/407) in female subjects. The mean values of APC-SR (1,64 in male and 1,71 in female subjects) were not significantly different (P = 0,22). Based on these results, we conclude that the prevalence of APC resistance in Albanian population of Kosovo is within the lower limit of prevalence in general population in different countries of European countries, which, according to some authors ranges is from 3 to 7%.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002000      PMCID: PMC5603690          DOI: 10.17305/bjbms.2009.2789

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  34 in total

1.  Prevalence of mild hyperhomocysteinaemia and association with thrombophilic genotypes (factor V Leiden and prothrombin G20210A) in Italian patients with venous thromboembolic disease.

Authors:  V De Stefano; B Zappacosta; S Persichilli; E Rossi; I Casorelli; K Paciaroni; P Chiusolo; A M Leone; B Giardina; G Leone
Journal:  Br J Haematol       Date:  1999-08       Impact factor: 6.998

2.  High prevalence of factor V mutation (Leiden) in the Eastern Mediterranean.

Authors:  N Irani-Hakime; H Tamim; G Elias; R R Finan; J L Daccache; W Y Almawi
Journal:  Clin Chem       Date:  2000-01       Impact factor: 8.327

3.  Factor V Leiden in blood donors in Baghdad (Iraq).

Authors:  Nasir A Al-Allawi; Jaladet M S Jubrael; Ferial A Hilmi
Journal:  Clin Chem       Date:  2004-03       Impact factor: 8.327

4.  Prevalence of factor V Leiden in the Chinese population.

Authors:  C H Ho; W K Chau; H C Hsu; J P Gau; C M Chih
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  1999-12

5.  Frequency of a defective response to activated protein C in patients with a history of venous thrombosis.

Authors:  Y Cadroy; P Sié; B Boneu
Journal:  Blood       Date:  1994-04-01       Impact factor: 22.113

Review 6.  Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.

Authors:  B Dahlbäck
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

Review 7.  Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.

Authors:  D T Price; P M Ridker
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

8.  Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries.

Authors:  A Dacosta; B Tardy-Poncet; K Isaaz; A Cerisier; P Mismetti; S Simitsidis; J Reynaud; B Tardy; M Piot; H Decousus; D Guyotat
Journal:  Heart       Date:  1998-10       Impact factor: 5.994

9.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

Authors:  M den Heijer; T Koster; H J Blom; G M Bos; E Briet; P H Reitsma; J P Vandenbroucke; F R Rosendaal
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

10.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study.

Authors:  T Koster; F R Rosendaal; H de Ronde; E Briët; J P Vandenbroucke; R M Bertina
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321

View more
  3 in total

1.  Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.

Authors:  Mehrez M Jadaon
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-09-08       Impact factor: 2.576

2.  Prevalence and role of antithrombin III, protein C and protein S deficiencies and activated protein C resistance in Kosovo women with recurrent pregnancy loss during the first trimester of pregnancy.

Authors:  Ymer Mekaj; Shefqet Lulaj; Fetie Daci; Naser Rafuna; Ermira Miftari; Hakif Hoxha; Xhemile Sllamniku; Agon Mekaj
Journal:  J Hum Reprod Sci       Date:  2015 Oct-Dec

3.  Vascular Genetic Variants and Ischemic Stroke Susceptibility in Albanians from the Republic of Macedonia.

Authors:  Bajram Kamberi; Farije Kamberi; Mirko Spiroski
Journal:  Open Access Maced J Med Sci       Date:  2016-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.